CATEGORY: SLEEP & RECOVERY
Plenty of people with sleep apnea own a CPAP machine that now sits in a closet. For them there has never been a drug to take instead. A once-nightly pill has now come through the first completed phase 3 trial of a medicine for obstructive sleep apnea. Over 26 weeks it reduced breathing interruptions by an estimated 44% in 646 adults who could not tolerate CPAP or had turned it down. Placebo managed 18%.1 About one in six pill takers reached the normal range, roughly twice the placebo share. For most, the condition eased rather than lifted.
Why the Airway Gives Way at Night
In obstructive sleep apnea, the muscles holding the throat open go slack during sleep, and the airway narrows or collapses over and over. Each collapse briefly cuts off oxygen and jolts the sleeper toward waking. Most people never know it happened. The standard fix is CPAP, a bedside machine that pushes a steady stream of air through a mask to splint the airway open. It works. Living with the mask is the hard part, and many people give up on it.
Two Old Drugs Recruited for the Night Shift
The pill, called AD109, combines two existing ingredients. Atomoxetine has long been used for attention-deficit disorder, and aroxybutynin is a chemical relative of a bladder medicine. Together they strengthen the nerve signals that keep the tongue and throat muscles firm through the night. CPAP holds the airway open from outside with air pressure. This pill aims at the airway’s own muscular scaffolding, telling the night shift to stay at its post rather than sending in reinforcements.
Sleep Labs at Both Ends of Six Months
The bottles were handed out by a randomization list, not by preference. Across 69 centers in the United States and Canada, 646 adults got the nightly pill or a matching placebo, and nobody in the room knew which. Participants averaged their late 50s, about half were women, and their apnea ran mild (35%), moderate (42%) and severe (23%). Overnight sleep studies at the start and again at week 26 counted the apnea-hypopnea index, the number of times an hour that breathing pauses or shallows. At the start, the typical participant’s breathing was interrupted about 20 times an hour. That is once every three minutes, all night.
By week 26, the model-estimated drop in breathing interruptions was 44.1% on the pill and 17.6% on placebo.1 The share whose apnea fell below five interruptions an hour, the normal range, was 17.6% versus 9.3%. Improvement by at least one severity category reached 41.8% versus 33.6%. Hypoxic burden, a measure of how much low oxygen the body endured overnight, fell about 45% on the pill against 8.5% on placebo. The gains held across mild, moderate and severe disease. Most pill takers still had sleep apnea when the trial ended.
The Score That Did Not Move, and Who Quit
Fatigue was tracked too, and there the answer came back flat. Tiredness scores improved in both groups, and the difference between pill and placebo was not statistically significant. Side effects included dry mouth, nausea, insomnia and hesitancy in urination. They led 21.2% of pill takers to stop, versus 3.1% on placebo, with no serious treatment-related events reported. The drug is not approved. Its maker has filed with US regulators, and a decision is expected in 2027.
Key Takeaways
- Over 26 weeks the nightly pill cut breathing interruptions by an estimated 44%, against 18% on placebo, in 646 adults who could not or would not use CPAP. It is the first completed phase 3 trial of a drug for the condition.
- About one in six pill takers reached the normal range of fewer than five interruptions an hour, against about one in eleven on placebo. That is an improvement, not a cure.
- Self-reported fatigue improved about equally in both groups, and roughly one in five stopped the pill over side effects such as dry mouth and insomnia.
- The pill remains investigational, with US regulators reviewing it and a decision expected in 2027.
References
- Strollo PJ, et al. Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy). Am J Respir Crit Care Med. 2026;212(7):1569–1584. link